Literature DB >> 20964641

Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?

G P Sandilands1, M Wilson, C Huser, L Jolly, W A Sands, C McSharry.   

Abstract

The precise biological mechanisms that caused the TGN1412 clinical trial tragedy (also known as 'The Elephant Man Clinical Trial') in March 2006 remain a mystery to this day. It is assumed widely that the drug used in this trial (TGN1412) bound to CD28 on T lymphocytes and following activation of these cells, a massive 'cytokine storm' ensued, leading ultimately to multi-organ failure in all recipients. The rapidity of this in vivo response (within 2 h), however, does not fit well with a classical T lymphocyte response, suggesting that other 'faster-acting' cell types may have been involved. In this study we have activated purified human peripheral blood leucocyte populations using various clones of mouse monoclonal anti-CD28 presented to cells in the form of a multimeric array. Cytokines were measured in cell-free supernatants at 2 h, and specific mRNA for tumour necrosis factor (TNF)-α, thought to be the initiator of the cytokine storm, was also measured in cell lysates by reverse transcription-polymerase chain reaction (RT-PCR). Monocytes were the only cell type found to show significant (P < 0·05) up-regulation of TNF-α at 2 h. Eleven other monocyte cytokines were also up-regulated by anti-CD28 within this time-frame. It therefore seems likely that monocytes and not T cells, as widely believed, were probably responsible, at least in part, for initiating the cytokine storm. Furthermore, we propose that a multimeric antibody array may have formed in vivo on the vascular endothelium via an interaction between TGN1412 and CD64 (FcγRI), and we provide some evidence in support of this hypothesis.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20964641      PMCID: PMC3026555          DOI: 10.1111/j.1365-2249.2010.04264.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

Review 1.  NKT cells: facts, functions and fallacies.

Authors:  D I Godfrey; K J Hammond; L D Poulton; M J Smyth; A G Baxter
Journal:  Immunol Today       Date:  2000-11

Review 2.  Biology of human immunoglobulin G Fc receptors.

Authors:  J G van de Winkel; C L Anderson
Journal:  J Leukoc Biol       Date:  1991-05       Impact factor: 4.962

3.  Immunobiology of CD28 expression on human neutrophils. I. CD28 regulates neutrophil migration by modulating CXCR-1 expression.

Authors:  K Venuprasad; P Parab; D V Prasad; S Sharma; P R Banerjee; M Deshpande; D K Mitra; S Pal; R Bhadra; D Mitra; B Saha
Journal:  Eur J Immunol       Date:  2001-05       Impact factor: 5.532

4.  Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha.

Authors:  D B Dubravec; D R Spriggs; J A Mannick; M L Rodrick
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Human neutrophil-expressed CD28 interacts with macrophage B7 to induce phosphatidylinositol 3-kinase-dependent IFN-gamma secretion and restriction of Leishmania growth.

Authors:  K Venuprasad; Pinaki P Banerjee; Subhasis Chattopadhyay; Satyan Sharma; Subrata Pal; P B Parab; Debashis Mitra; Bhaskar Saha
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

Review 6.  Eokines: synthesis, storage and release from human eosinophils.

Authors:  P Lacy; R Moqbel
Journal:  Mem Inst Oswaldo Cruz       Date:  1997       Impact factor: 2.743

7.  Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro.

Authors:  M Gröger; G Sarmay; E Fiebiger; K Wolff; P Petzelbauer
Journal:  J Immunol       Date:  1996-02-15       Impact factor: 5.422

8.  Chlamydophila pneumoniae infection of human aortic endothelial cells induces the expression of FC gamma receptor II (FcgammaRII).

Authors:  Silvana Vielma; Gabriel Virella; Adam Gorod; Maria Lopes-Virella
Journal:  Clin Immunol       Date:  2002-09       Impact factor: 3.969

9.  Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha.

Authors:  J J Costa; K Matossian; M B Resnick; W J Beil; D T Wong; J R Gordon; A M Dvorak; P F Weller; S J Galli
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

10.  CD28 signaling in neutrophil induces T-cell chemotactic factor(s) modulating T-cell response.

Authors:  K Venuprasad; Subhasis Chattopadhyay; Bhaskar Saha
Journal:  Hum Immunol       Date:  2003-01       Impact factor: 2.850

View more
  7 in total

Review 1.  Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

Authors:  Joseph M Ryan; Jeffrey S Wasser; Adam J Adler; Anthony T Vella
Journal:  Expert Opin Biol Ther       Date:  2016-02-25       Impact factor: 4.388

2.  Granzyme B- and Fas ligand-mediated cytotoxic function induced by mitogenic CD28 stimulation of human memory CD4+ T cells.

Authors:  Miguel A Medina; Jacob Couturier; Marsha L Feske; Ashley E Mahne; Mary Turner; Xiaoyong Yu; Claudia A Kozinetz; Aaron F Orozco; Alexander T Hutchison; Tor C Savidge; John R Rodgers; Dorothy E Lewis
Journal:  J Leukoc Biol       Date:  2012-03-13       Impact factor: 4.962

3.  CD28 ligation increases macrophage suppression of T-cell proliferation.

Authors:  Daniel Silberman; Amanda Bucknum; Thomas Bartlett; Gabriella Composto; Megan Kozlowski; Amanda Walker; Amy Werda; Jackelyn Cua; Arlene H Sharpe; John E Somerville; James E Riggs
Journal:  Cell Mol Immunol       Date:  2012-04-23       Impact factor: 11.530

4.  Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.

Authors:  Thilipan Thaventhiran; Naif Alhumeed; Han X A Yeang; Swaminathan Sethu; Jocelyn S Downey; Ahmad F Alghanem; Adedamola Olayanju; Emma L Smith; Michael J Cross; Steven D Webb; Dominic P Williams; Adrian Bristow; Christina Ball; Richard Stebbings; Jean G Sathish
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

5.  After TGN1412: recent developments in cytokine release assays.

Authors:  R Stebbings; D Eastwood; S Poole; R Thorpe
Journal:  J Immunotoxicol       Date:  2012-09-11       Impact factor: 3.000

6.  Dynamics of a cytokine storm.

Authors:  Hao Hong Yiu; Andrea L Graham; Robert F Stengel
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

Review 7.  "Cytokine storm", not only in COVID-19 patients. Mini-review.

Authors:  Norbert Lukan
Journal:  Immunol Lett       Date:  2020-09-29       Impact factor: 3.685

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.